ReviewLife (Basel, Switzerland)2023
Future Comorbidities in an Aging Cystic Fibrosis Population.
Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Long-term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real-world cohort study.British journal of clinical pharmacology · 2026Article
- Feasibility and Tolerance of High-Intensity Interval Training in Adults With Cystic Fibrosis.Archives of rehabilitation research and clinical translation · 2026Article
- Cystic Fibrosis: A Disease with a New Face.Life (Basel, Switzerland) · 2026Article
- Pulmonary hypertension in pediatric patients with cystic fibrosis during acute pulmonary exacerbations: prevalence and associated factors.BMC pulmonary medicine · 2026Article
- The clinical, psychosocial, and economic burden of cystic fibrosis lung disease in the era of CFTR modulator therapy.Annals of the American Thoracic Society · 2026Review
- Enteroendocrine cell differentiation: Implications for human disease.Molecular and cellular endocrinology · 2025Review
- Review
- Evolving nutrition therapy in cystic fibrosis: Adapting to the CFTR modulator era.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2025Review
- Managing an ageing cystic fibrosis population: challenges and priorities.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Current Blood Eosinophilia Does Not Predict the Presence of Pulmonary Hypertension in Patients with End-Stage Lung Disease.Journal of clinical medicine · 2025Article
- Aging with CF: Characteristics of people with CF aged 40 and older in the United States.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2025Article
- Hepatocellular Carcinoma in Cystic Fibrosis Liver Disease.Gastro hep advances · 2025Article
- Opportunistic Screening for Low Bone Mineral Density in Adults with Cystic Fibrosis Using Low-Dose Computed Tomography of the Chest with Artificial Intelligence.Journal of clinical medicine · 2024Article
- Standards of care and educational gaps in adult cystic fibrosis units: a European Respiratory Society survey.ERJ open research · 2024Article
- Unity Is Strength: The Mutual Alliance between CFTR and SLC26A6 as Therapeutic Opportunity in Cystic Fibrosis.Pharmaceuticals (Basel, Switzerland) · 2024Article
- An Update in Cystic Fibrosis-Related Diabetes in Children and Adolescents.Children (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic fibrosis (CF) is an autosomal recessive disease due to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. With the advent of highly effective modulator therapy targeting the abnormal CFTR protein, people with CF (PwCF) are living more than 40 years longer than the pre-modulator therapy era. As a result, PwCF are facing new challenges of managing similar comorbidities affecting the average aging population. While CF is notoriously identified as a chronic respiratory disease, the multisystem presence of the CFTR gene can contribute to other organ-related complications acutely, but also heighten the likelihood of chronic conditions not routinely encountered in this cohort. In this overview, we will focus on risk factors and epidemiology for PwCF as they relate to cardiovascular disease, dyslipidemia, CF-related diabetes, pulmonary hypertension, obstructive sleep apnea, CF-liver disease, bone health and malignancy. With increased awareness of diseases affecting a newly aging CF population, a focus on primary and secondary prevention will be imperative to implementing a comprehensive care plan to improve long-term morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.